key: cord-0759111-gp16np8f
authors: Bergeri, I.; Whelan, M.; Ware, H.; Subissi, L.; Nardone, A.; Lewis, H. C.; Li, Z.; Ma, X.; Valenciano, M.; Cheng, B.; Al Ariqi, L.; Rashidian, A.; Okeibunor, J.; Azim, T.; Wijesinghe, P.; Le, L.-V.; Vaughan, A.; Pebody, R.; Vicari, A.; Yan, T.; Yanes-Lane, M.; Cao, C.; Cheng, M. P.; Papenburg, J.; Buckeridge, D.; Bobrovitz, N.; Arora, R. K.; van Kerkhove, M. D.; Group, Unity Studies Collaborator
title: Global epidemiology of SARS-CoV-2 infection: a systematic review and meta-analysis of standardized population-based seroprevalence studies, Jan 2020-Oct 2021
date: 2021-12-15
journal: nan
DOI: 10.1101/2021.12.14.21267791
sha: 2a7bdd36e604e69aed10afa9bd458837e1fd68ac
doc_id: 759111
cord_uid: gp16np8f

Background COVID-19 case data underestimates infection and immunity, especially in low- and middle-income countries (LMICs). We meta-analyzed standardized SARS-CoV-2 seroprevalence studies to estimate global seroprevalence. Objectives/Methods We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence studies aligned with the WHO UNITY protocol published between 2020-01-01 and 2021-10-29. Eligible studies were extracted and critically appraised in duplicate. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate under-ascertainment; meta-analyzed differences in seroprevalence between demographic subgroups; and identified national factors associated with seroprevalence using meta-regression. PROSPERO: CRD42020183634. Results We identified 396 full texts reporting 736 distinct seroprevalence studies (41% LMIC), including 355 low/moderate risk of bias studies with national/sub-national scope in further analysis. By April 2021, global SARS-CoV-2 seroprevalence was 26.1%, 95% CI [24.6-27.6%]. Seroprevalence rose steeply in the first half of 2021 due to infection in some regions (e.g., 18.2% to 45.9% in Africa) and vaccination and infection in others (e.g., 11.3% to 57.4% in the Americas high-income countries), but remained low in others (e.g., 0.3% to 1.6% in the Western Pacific). In 2021 Q1, median seroprevalence to case ratios were 1.9:1 in HICs and 61.9:1 in LMICs. Children 0-9 years and adults 60+ were at lower risk of seropositivity than adults 20-29. In a multivariate model using data pre-vaccination, more stringent public health and social measures were associated with lower seroprevalence. Conclusions Global seroprevalence has risen considerably over time and with regional variation, however much of the global population remains susceptible to SARS-CoV-2 infection. True infections far exceed reported COVID-19 cases. Standardized seroprevalence studies are essential to inform COVID-19 control measures, particularly in resource-limited regions.

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, continues to severely impact population health and health care systems. The 250 million cases and 5 million deaths reported as of 9 November 2021 (1) underestimate the global burden of this pandemic, particularly in low-and middle-income countries (LMICs) with limited capacity for contact tracing, diagnostic testing, and surveillance capacity (2).

Seroprevalence studies estimate the prevalence of SARS-CoV-2 antibodies. These studies are crucial to understand the true extent of infection overall, by demographic group, and by geographic area, as well as to estimate case underascertainment. As anti-SARS-CoV-2 antibodies are highly predictive of immune protection (3, 4) , seroprevalence studies are also indicative of population levels of protection, and therefore important to inform scenario modeling, public health planning, and national policies in response to the pandemic.

During 2021, many regions have experienced third and fourth waves of SARS-CoV-2 infection(1); concurrently, some countries have vaccinated most residents, while others remain unable to achieve high vaccine coverage due to challenges with supply and uptake (5) . A new wave of well conducted seroprevalence studies, including many in LMICs, provides robust estimates of seroprevalence in late 2020 and 2021 (6) (7) (8) . Synthesizing these studies is crucial to understand the shifting global dynamics and true extent of SARS-CoV-2 infection, humoral immunity, and population susceptibility. Previous global systematic reviews of seroprevalence (8) (9) (10) (11) largely pooled results from all studies done in 2020, and have not systematically examined changes in seroprevalence over time. Moreover, these reviews have limited LMIC coverage (11-23% of included studies), meaning their findings may not equitably represent global seroprevalence. These meta-analyses also highlight the importance of improved standardization and study quality to enable more robust analysis (9) (10) (11) .

Estimates of seroprevalence can be difficult to compare systematically across different settings due to variations in design aspects including sampled populations, testing and analytical methods, timing in relation to waves of infection, and study quality and reporting. The World Health Organization's UNITY Initiative aims to help produce harmonized and representative seroprevalence study results in accordance with global equity principles (2). The UNITY population-based, age-stratified seroepidemiological investigation protocol (the SEROPREV protocol) (2) provides a standard study design and laboratory approach to general population seroprevalence studies. WHO UNITY and its partners have supported the implementation of SEROPREV by providing financial and technical resources, including a well-performing serologic assay. SEROPREV has been implemented in 74 countries globally and in 51 LMICs as of September 2021 (12) , enabling further analysis of these comparable studies to answer key questions about the progress of the pandemic globally.

This systematic review and meta-analysis synthesized seroprevalence studies worldwide aligned with the WHO SEROPREV protocol, regardless of whether the study received support from WHO. Our objectives were to: (i) estimate changes in global and regional seroprevalence over time by WHO region and country income level, including LMICs; (ii) assess the level of undetected infection, by global and regional case ascertainment over time by calculating the ratio of seroprevalence to reported cases; and (iii) identify factors associated with seropositivity including demographic differences by 10-year age band and sex through meta-analysis, and study design and country-level differences such as public health and social measure (PHSM) stringency through multivariable meta-regression.

We conducted a systematic review of seroprevalence studies (hereafter "studies") published from 1 January 2020 to 29 October 2021. We designed a search strategy in MEDLINE, Embase, Web of Science, and Europe PMC using key terms such as SARS-COV-2, COVID-19, seroprevalence, and serology; We included published research articles, preprints, institutional reports, grey literature, and media reports (full strategy in Supplementary file S.3.1). We also contacted WHO UNITY study collaborators that had not yet made results available to the general public prior to our inclusion dates, to upload their aggregated, standardized results to the Zenodo research data repository (13) . This systematic review and meta-analysis is registered with PROSPERO (CRD42020183634) (14) , reported according to the PRISMA guidelines (15) (Supplementary file S1), and search and extraction conducted per the SeroTracker protocol (16) .

Studies were screened, and data were extracted, and critically appraised by two independent researchers. Conflicts were resolved by consensus. The following inclusion and exclusion criteria were designed to align with the SEROPREV protocol (Supplementary File S2.2 and S2.3). We searched for and included studies regardless of whether they explicitly cited following the SEROPREV Unity protocol. Briefly, we included studies that were cross-sectional or longitudinal cohort studies with the objective of estimatingSARS-CoV-2 seroprevalence in the general population (see S.2.1 for list of included sampling frames). Both random or non-random (i.e., convenience, sequential, quota) sampling methods were included. Studies had to use serological assays with at least 90% sensitivity and 97% specificity as reported by the manufacturer or study authors (Supplementary file S2.1), unless conducted in vulnerable countries as defined in the Global Humanitarian Response Plan (HRP) (17) . Multi-assay testing algorithms were included if the combined sensitivity and specificity met these performance thresholds (18) . We excluded studies sampling specific closed populations (such as prisons, care homes, or other single-institution populations), recruiting participants without a clear sampling frame approximating the target population or testing strategy, and studies that excluded people previously diagnosed with or vaccinated against COVID-19 after initial sampling.

From each study, we extracted seroprevalence estimates for the overall sample, and stratified by age, sex, vaccination status, and timing of specimen collection. We extracted information on study population, laboratory assay used, any corrections made in estimating seroprevalence (e.g., for population or assay performance), seroprevalence, and denominator. Standardized results uploaded to Zenodo by UNITY study collaborators additionally included information on the proportion of asymptomatic seropositive individuals.

We critically appraised all studies using a modified version of the Joanna Briggs Institute (JBI) checklist for prevalence studies (19) . JBI checklist ratings were initially completed for each study by two independent reviewers, with conflicts resolved by consensus. To assess the overall risk of bias for studies included in this review, we used an automated decision rule that assigned a rating of low, moderate, or high risk of bias based on the specific combination of JBI checklist ratings for that study (20) . This decision rule was developed based on guidance on estimating disease prevalence (21, 22) and was validated against overall risk of bias assessments derived manually by two independent reviewers for previously collected seroprevalence studies in the SeroTracker database, showing good agreement with manual review (intraclass correlation 0.77, 95% CI 0.74-0.80; n = 2070 studies) (20) .

We classified seroprevalence studies by geographic scope (local, sub-national, or national), sample frame, sampling method, and type of serological assay (Supplement S2.1, Countries were classified according to WHO region (23), vulnerability via HRP status (17), and World Bank income level. We stratified the European Region (EUR) and Region of the Americas (AMR) by highincome countries (HIC) and LMICs due to inter-country diversity in pandemic responses and vaccine rollout (24) . We pooled HIC and LMIC together in the Eastern Mediterranean (EMR) and Western Pacific region (WPR) due to the lower number of studies. In the Africa (AFR) and South-East Asia regions (SEAR), we pooled LMIC (the only two HIC in these regions, Mauritius and Seychelles, had no studies).

As all non-HRP studies used assays with at least 90% sensitivity and at least 97% specificity, we used seroprevalence estimates uncorrected for test characteristics. We anchored each estimate to the date halfway between sampling start and end ("sampling midpoint date") to best reflect the time period of the study.

We described the characteristics of all identified studies (dataset 0). To select the most representative and high quality studies for analysis, we used only sub-national or national studies rated low or moderate risk of bias to estimate seroprevalence in the general population over time and identify factors associated with seroprevalence (sub-dataset 1). Finally, we used only national studies rated low or moderate risk of bias to estimate case ascertainment (sub-dataset 2).

To estimate monthly regional and global population-weighted seroprevalence in the general population, we first grouped studies in 8-week rolling windows by country and pooled effect sizes by random-effects metaanalysis, then produced regional estimates as weighted averages by country population (25) . Global . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267791 doi: medRxiv preprint estimates were population-weighted averages of regional estimates (full details: Supplement S3.2). We produced 95% confidence intervals for the mean seroprevalence estimate, reflecting uncertainty in the summary effect size (26) . To capture the trend in seroprevalence, we used nonparametric regression to fit a smooth function of time to the meta-analysis estimates (full details: Supplement S3.2).

We also estimated to what extent confirmed SARS-CoV-2 cases, as reported to WHO (27) , underestimated the true burden of disease based on seroprevalence studies. First, for studies that sampled participants in 2021, we used national seroprevalence estimates and vaccination rates (Our World In Data(28)) to calculate seroprevalence attributable to infection only. In countries administering only vaccines using Spike (S) protein antigens (e.g., mRNA, viral vector), we calculated the ascertainment ratio using only studies that detected anti-nucleocapsid (N) seroprevalence, as a proxy for infection-induced seroprevalence. In countries administering inactivated vaccines that may generate both anti-S and anti-N responses (e.g., Sinopharm, Bharat Biotech), we adjusted the reported seroprevalence based on the vaccination rate in the country of the study using a standard formula (29) . We then produced regional and global estimates of seroprevalence using the steps in the previous paragraph, and computed the ratio to the corresponding cumulative incidence of confirmed SARS-CoV-2 cases. We stratified by HIC vs. LMIC in all regions to identify any trends in ascertainment by income level.

Aggregated results shared by UNITY collaborators reported the proportion of seropositives that were symptomatic at some time point prior to sampling (dependent on individual study parameter definitions), which were summarized using the median and interquartile range, and tested for differences in distribution across age and sex groups using the Kruskal-Wallis H-test.

To quantify population differences in SARS-CoV-2 seroprevalence, we identified studies with seroprevalence estimates for sex and age subgroups. We calculated the ratio in seroprevalence between groups within each study, comparing each age group to adults 20-29 and males to females. We then aggregated the ratios across studies using inverse variance-weighted random-effects meta-analysis. The amount of variation attributable to between-study heterogeneity vs. within-study variance was quantified using the I 2 statistic.

To examine study and national factors affecting seroprevalence estimates, we constructed a Poisson generalized linear mixed-effects model (30) . To focus on factors associated with seroprevalence from infection, we excluded studies where over 5% of the national population was vaccinated two weeks before the sampling midpoint date. Independent predictors were defined a priori as WHO region, income group, geographic scope, sample frame, transmission phase (i.e. pandemic timing; before peak of 1st wave, after peak of 1st wave, or after peak of 2nd wave), cumulative confirmed cases, and average London School of Hygiene and Tropical Medicine (LSHTM)/WHO public health and social measure (PHSM) stringency index (31) . We compared the full model to all models dropping a single predictor at a time and selected the model with the lowest Akaike Information Criterion (AIC) (full details on the model and predictor definitions: Supplement S3.2).

Data was analyzed using R statistical software version 4.1.0 (32).

We identified 69,528 titles and abstracts in our search, of which 17,108 were grey literature and 37 were aggregated results from WHO UNITY study collaborators ( Figure 1 ). Of these, 4,682 full text articles were included in full text screening. 396 seroprevalence data sources aligned with the SEROPREV protocol were . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267791 doi: medRxiv preprint included, 370 published and 26 aggregated results from collaborators, that contained a total of 736 unique seroprevalence studies included from 396 full-text sources (detailed references and information available in Supplement, S4.1-S4.3, S5).

In cases where sources contained multiple primary estimates of seroprevalence (i.e. in non-overlapping populations, separate methodological seroprevalence studies reported in the same article, etc), the source (full text) was split into multiple individual studies included in the analysis. For this reason, we report more unique seroprevalence studies than original full text articles included. (Figure 2 ). Data from 53 of 135 LMICs and from 29 of 63 vulnerable HRP countries were included. A large proportion of studies included in the descriptive analysis were conducted in LMIC (41%) and in vulnerable HRP countries (21%). Of studies included in the meta-analysis and metaregression, these proportions were 31% and 15%, respectively.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267791 doi: medRxiv preprint

Among the 736 studies included in the descriptive analysis, 41% reported results at a local level, 36% at a national level, and 24% at a sub-national level. The most common sampling frame and method was households (52%) and probability sampling (58%), respectively. Among the testing strategies used to measure seroprevalence, most studies used ELISA (39%) or CLIA assays (32%) and few studies used a lateral flow immunoassay (12%) or multiple assay testing algorithm (8.6%). A small proportion of included studies from vulnerable countries (7.1%, 52/736) used tests that fell below the 90% sensitivity or 97% specificity threshold. The majority of studies (86%) had no vaccination at the sampling midpoint date in the country of the study (Table 1) .

Most (49%) studies were rated moderate risk of bias, followed by high risk of bias (29%) and low risk of bias (21%). A summary of overall risk of bias ratings and breakdown of each risk of bias indicator for all studies is available ( Figure S1 and Table S8 , respectively). In this meta-analysis of observational studies, most studies were not pre-registered and the seroprevalence estimated typically would not influence an attempt to publish. Snapshots of seroprevalence to confirmed case ratios (ascertainment), based on estimated populationweighted seroprevalence using national studies, are shown in Table 2 . Globally, the median ratio was 34:1 in 2020 Q3 and 16:1 in 2021 Q1. In 2020 Q3, the median ratio ranged from 5:1 in AMR (HIC) to 183:1 in EMR (LMIC). In 2021 Q1, this ranged from 2:1 in EUR (HIC) to 185:1 in AFR (Table 2) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267791 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267791 doi: medRxiv preprint Figure 3 . Reported seroprevalence from January 2020 to June 2021, and average population-weighted seroprevalence globally and by WHO region from January 2020 to April 2021. We produced population-weighted point estimates of seroprevalence by grouping studies in 8-week rolling windows, prioritizing national studies, and weighting reported seroprevalence by study sample size and country population. To capture the trend in seroprevalence in each WHO region and globally, we fit a flexible, smooth function of time using to the point estimates using non-parametric regression (full details: Supplement S.4.2). Cumulative incidence data is sourced from WHO; vaccine administration data, measuring the number of people per region with at least a first dose of a COVID-19 vaccine, is sourced from OWID. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint We calculated the ratio in prevalence between subgroups within each study then aggregated the ratios across studies using inverse variance-weighted random-effects meta-analysis. Heterogeneity was quantified using the I 2 statistic. Each row represents a separate meta-analysis. Right panel: Regression results. We fit a log-Poisson generalized linear mixed-effects model, excluding studies where over 5% of the geographic population had received at least one dose of any vaccine. We performed model comparison and selected the model with the lowest AIC criterion (Appendix 6). Sampling frame was dropped from the final model. Public health and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267791 doi: medRxiv preprint social measures (PHSM) data was taken from the London School of Hygiene and Tropical Medicine global dataset. The PHSM index scale ranged from 0 (least stringent) to 10 (most stringent) (see Supplement S4). k = 282; 2 (se) = 0.76 (0.87). The marginal R2, or variation between studies explained only by fixed effects, was 60.4%. (1) Multivariate analysis included additional controls for WHO region and transmission phase not shown in figure.

We synthesized data from over 700 seroprevalence studies worldwide (41% from LMIC) published up to October 2021, providing global and regional estimates of SARS-CoV-2 seroprevalence over time with substantial representation of regions with limited available seroprevalence data. We estimate that approximately one quarter (26.1%) of the global population has antibodies against SARS-CoV-2 in April 2021 (21.0% when excluding vaccination). Global seroprevalence has risen considerably over time, from 8.3% in October 2020.

Our findings provide evidence of regional variation in the estimated seroprevalence, from 1.6% in WPR in February 2021 to 43-46% in SEAR, EMR and AFR in February-April 2021 and up to 57% in AMR HIC. Regional variation is driven by differences in the extent of SARS-CoV-2 infection and vaccination. This is exemplified by our monthly timeline of seroprevalence by region, 2020-2021, which provides estimates of evolving temporal changes of the global pandemic. This timeline shows rapid increases in seroprevalence since December 2020 due to infection in some regions (e.g., 18% to 46% in AFR) and vaccination and infection in others (e.g., 11% to 57% in the AMR HIC), while seroprevalence in other regions remains low (e.g., 0.3% to 1.6% in WPR). Our analysis adds global representation and principled estimation of changes in seroprevalence over time as compared to previous evidence syntheses ( [8] [9] [10] . These estimates are similar to estimates of true infections by global epidemiological models. For example, our global estimate of seroprevalence attributable to infection (21%) is similar to the Institute of Health Metrics and Evaluation cumulative infection incidence estimate of 24% in mid-April 2021 (34) . Our analysis provides an orthogonal estimate based solely on seroprevalence data, using a method that has the added value of being easily interpretable and with fewer assumed parameters.

Our results provide evidence of considerable case under-ascertainment, indicating that many cases of SARS-CoV-2, including subclinical cases, are not captured by surveillance systems which in many countries are based on testing of symptomatic patients. There was wide variation in under-ascertainment (as estimated through seroprevalence-case ratios) in all regions, income groups and over time, with higher ratios consistently observed in LMICs compared to HICs. Our ratios of seroprevalence to reported cases in late 2020 were comparable to other studies for AMR, EUR, and SEAR (9) (10) (11) (12) . Our estimates of seroprevalence to case ratios for AFR, WPR, and EMR are novel, with no other analyses we found having systematically estimated ascertainment through seroprevalence in these regions; moreover, estimates of true infections from epidemiological models suggest the high levels of under-ascertainment suggested by this study are plausible (34) .

We also provide more granular evidence of significant variation in infection by age by 10-year band. Children aged <10 years, but not children aged 10-19, were less likely to be seropositive compared to adults aged 20-29 years; similarly, adults aged >60 years, but not those aged 30-39, 40-49, or 50-59, were less likely to be seropositive than adults 20-29. These findings add nuance and granularity to differences in seroprevalence by age observed by other studies (10) . Lower seroprevalence in adults 60+ could be explained by immunosenescence that can lead to quicker seroreversion (35) , higher mortality and hence a lower proportion of individuals with evidence of past infection, or more cautious behaviour resulting in fewer infections in this age group. There are several possible explanations for lower seroprevalence in children: milder infections, which are generally associated with lower antibody titers (36); school closures; and ineligibility for vaccination.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ;  We found that, in a multivariate model including geographic region, income class, and transmission phase, an increase in overall PHSM stringency was associated with lower seroprevalence. Our and other work has shown that the use of PHSM was associated with reduced SARS-CoV-2 infections, especially when implemented early and limiting population mobility (37-39).

Our regional and global meta-analysis estimates are timely, robust and geographically diverse with estimates from all WHO regions. The laboratory and epidemiological standardization enabled by the SEROPREV protocol, as well as the inclusion of only studies assessed to have low or moderate risk of bias using a validated risk of bias tool (20) , enabled analysis of high-quality and comparable data. In line with the equity principles of the UNITY initiative, our dataset had global coverage, including a broad range of LMICs (one third of studies included in our meta-analysis of seroprevalence over time, n=109) and vulnerable HRP countries (15% of included studies). UNITY study collaborators shared timely evidence by uploading their aggregated and standardized early results to an open data repository, enabling geographic coverage and reducing publication bias.

A few limitations were encountered during the course of this study.. First, although we conducted metaregression to explore heterogeneity of the included studies, there remained some residual heterogeneity that could not be explained quantitatively -likely driven by differences in disease transmission in the different countries and time points that serosurveys were conducted. Second, we did not account for waning of population immunity, so the present study likely underestimates the extent of past infection and case ascertainment. Thirdly, seroprevalence studies are cumulative, meaning that results reflect all COVID-19 countermeasures implemented up to the time of participant sampling and, thus, we cannot isolate the contributions of particular PHSM. Fourthly, while we screened study eligibility based on high assay performance criteria, different serological assays may yield varying results which should be taken into account when interpreting seroprevalence data. Finally, at certain points in time, our meta-analysis estimates were driven by studies from specific countries -either very populous countries (i.e. SEAR: India, AMR HIC: USA, AMR LMIC: Brazil, WPR: China), or countries in regions with scarce data during the time in question (e.g. EMR: 2 countries in early 2021). We also could not produce global estimates for mid to late 2021 due to the delays between when seroprevalence studies sampled participants and released results.

Our global estimates of infections based on seroprevalence far exceed reported cases. Seroprevalence has increased considerably in past months, due to infection in some regions and vaccination in others. Nevertheless, much of the global population remains susceptible to COVID-19. The pandemic persists in large because of inequitable access to pharmaceutical tools such as vaccines in LMIC; emphasizing the importance of equitable vaccine deployment globally, and of tailored PHSM to mitigate disease transmission until high population protection is achieved.

Seroprevalence studies have been invaluable throughout the COVID-19 pandemic to understand the true extent and dynamics over time of SARS-CoV-2 infection and immunity. These studies would be even more valuable if further standardized and their results made more rapidly available. As we enter the third year of the COVID-19 pandemic, we have the opportunity to develop a global system for continuous, multi-pathogen, and standardized serosurveillance (40, 41) . Through this learning process we have leveraged our knowledge and strengthened health system capacities, and built on the UNITY framework for standardized investigations. Implementing such a system would be a crucial next step to monitor the COVID-19 pandemic and contribute to readiness for other emerging respiratory pathogens. Globally standardised and quality seroprevalence data continue to be essential to inform health policy decision-making around COVID-19 control measures, particularly in capacity-limited regions, which are currently still not benefitting from equitable access to vaccines.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267791 doi: medRxiv preprint

Supplementary material file is attached. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267791 doi: medRxiv preprint Writing -review & editing: all authors.

All authors debated, discussed, edited, and approved the final manuscript. All authors had full access to the full data in the study and accepted responsibility to submit for publication.

Competing interests: WHO had a role in study design, data collection, data analysis, data interpretation, and writing of the report. No other funders had any such role. The corresponding authors had full access to all the data in the study and had final responsibility for the decision to submit for publication. Authors were not precluded from accessing data in the study, and they accept responsibility to submit for publication. 

Standardized results uploaded to Zenodo by UNITY study collaborators supporting the findings of this study are available at this community and DOIs for each included Zenodo study are cited in the Supplementary File (S5) https://zenodo.org/communities/unity-sero-2021?page=1&size=20 (13) . Summary datasets are available in Supplement S4. Open access datasets generated and analysed are available in a data repository (doi:10.5281/zenodo.5773152) and additional datasets are available from the Zenodo community upon request. All code necessary to reproduce this analysis will be added to a separate GitHub repository.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267791 doi: medRxiv preprint

Pui Shan Chung 9

Tri Yunis M Wahyono 79

Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID-19 pandemic. Influenza Other Respir Viruses

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Evidence for antibody as a protective correlate for COVID-19 vaccines

A global database of COVID-19 vaccinations

a cross-sectional, nationally representative, age-stratified serosurvey. medRxiv

SARS-CoV-2 seroprevalence among the general population and healthcare workers in India

SARS-COV-2 antibody seroprevalence in the general population of Oman: results from four successive nationwide seroepidemiological surveys

Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis

Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. Lancet Glob Health

Update on SARS-CoV-2 seroprevalence -Regional and worldwide

Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review

WHO Unity Global SARS-CoV-2 Seroepidemiological Investigations

A systematic review and metaanalysis of SARS-CoV-2 seroprevalence studies aligned with the WHO population-based seroepidemiological 'Unity' protocol CRD42020183634

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

SeroTracker: Our Data (Our Protocol)

Available from: serotracker.com/en/Data

COVID-19 Global Humanitarian Response Plan

United Nations Office for the Coordination of Humanitarian Affairs

Sensitivity and specificity of multiple tests

Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data

SeroTracker-ROB: reproducible decision rules for risk of bias assessment of seroprevalence studies

Quality assessment of prevalence studies: a systematic review

How are systematic reviews of prevalence conducted? A methodological study

World Health Organization. Regional offices

World Bank Country and Lending Groups

World Population Prospects -Population Division -United Nations

Cochrane Handbook for Systematic Reviews of Interventions (version 6.2)

WHO COVID-19 Case definition

World Health Organization

Coronavirus Pandemic (COVID-19) [Internet]. Our World in Data

COVID-19: Estimating the historical time series of infections

How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health

World Health Organization, London School of Hygiene and Tropical Medicine. Public Health and Social Measures

R: A language and environment for statistical computing

R Foundation for Statistical Computing

Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: systematic review. medRxiv

Institute for Health metrics and Evaluation (IHME). COVID-19 Estimates

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. The Lancet

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Inferring the effectiveness of government interventions against COVID-19

The Effect of Containment Measures on the COVID-19 Pandemic. IMF Work Pap

Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis

Opportunities and challenges of a world serum bankauthors' reply. The Lancet

A Global lmmunological Observatory to meet a time of pandemics. eLife

World Health Organization. Unity Studies: Early Investigation Protocols

This work was supported by WHO through funding from the WHO Solidarity Response Fund and the German Federal Ministry of Health COVID-19 Research and Development. IB, LS, AnV, LA, AR, JO,  TA, PW, LL, AiV, RP, MVK are employed by WHO, and HCL, AN, MV, BC are WHO consultants; the  authors alone are responsible We would especially like to thank all WHO UNITY Study Collaborator Group, who are also named coauthors of this paper and listed in the section below. These and other collaborators are recognized on a dedicated webpage on the UNITY and WHO website, (42) in all the countries who embarked in this global response effort to COVID-19, as well as all individuals who supported, conducted or participated in each of the studies supported.